Featured in this edition of iSpeak Reading Roundup, are the top blog posts from June 2020. Discover key insights for cleaning validation practices, risk-based approaches to quality, and more for what the pharmaceutical industry was reading last month.
The User Requirements Specification document contains requirements from multidisciplinary sources and supports design, commissioning and qualification activities, operations, and maintenance. Brief highlights of answers to FAQs from prior workshops.
The guide describes Good Engineering Practice as a quality system, governed by SOPs that Quality approve; Quality approve the user requirements specifications, System Risk Assessment (SRA) and the Qualification acceptance and release report; Engineering, the suitably trained and experienced experts, are responsible for completing installation and operational verification. But note that the guide also allows the testing that will be used to support qualification to be extracted and put into a separate document that Quality pre-and post-approve as seen in Guide
ISPE’s first virtual conference, the 2020 ISPE Biopharmaceutical Manufacturing Virtual Conference, is a new format for delivering education, information, and networking—a fitting first virtual meeting for ISPE given the cutting edge nature of the subject matter of biopharma, cell and gene therapies, and ATMPs. Like these technologies, ISPE and the conference attendees are adapting to new modalities—driven by the impacts of the COVID-19 pandemic—to embrace a new way of meeting and exchanging information.
We have all been given a lot of options lately. Google “things to do in quarantine” and you will have your pick from a slew of categories. With all these workout videos -- where to start? Which book to read? Make the trending Degong coffee or join my friends for an online Zumba class? Which conference platform is the best anyway, and why not try them all?
Making clinical trials more patient centric is among the many challenges facing the pharmaceutical industry. One method of improving the patient experience is by delivering study medication directly to patient homes, also known as Direct-to-Patient or DtP. However, the implementation of Direct-to-Patient may seem insurmountable in a highly regulated industry where specific regulations or guidance is lacking or vague. Additionally, Direct-to-Patient experiences can be inconsistent by country, trial, or therapeutic area.
The ISPE Sterile Products Processing Community of Practice (CoP) Steering Committee continues its series of blog posts, where committee members and other contributing subject matter experts dive into the validation and use of essential equipment and processes that drive sterile processing in the pharmaceutical industry. The aim is to provide practical insights that will enhance your...
Per- and polyfluoroalkyl substances (PFAS) have emerged as a major concern in the pharmaceutical industry and beyond. Restricting their use is heavily debated. On the one hand, these “forever chemicals” can pose environmental and human health risks. On the other hand, their unique physical and chemical properties can make them important for pharma and ultimately for helping to enable access to...